Last week, Novo Nordisk agreed to buy ocedurenone from KBP Biosciences for up to $1.3 billion. The drug treats uncontrolled hypertension and has potential applications in cardiovascular and kidney disease. Sirius Therapeutics has bagged $60 million in a Series B funding round led by Hankang Capital. Delos Capital participated in the round.